These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 17204182

  • 1. [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
    Huang WR, Li R, Jing Y, Zhang YZ, Wu XX, Gao CJ, Bo J, Yu L, Wang QS, Da WM.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec; 14(6):1146-50. PubMed ID: 17204182
    [Abstract] [Full Text] [Related]

  • 2. [Treatment with a proteasome inhibitor, bortezomib, for thalidomide-resistant multiple myeloma].
    Takatoku M, Noborio-Hatano K, Takahashi S, Kikuchi S, Mori M, Muroi K, Komatsu N, Ozawa K.
    Rinsho Ketsueki; 2004 Feb; 45(2):144-8. PubMed ID: 15045823
    [Abstract] [Full Text] [Related]

  • 3. A phase 2 study of bortezomib in relapsed, refractory myeloma.
    Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC.
    N Engl J Med; 2003 Jun 26; 348(26):2609-17. PubMed ID: 12826635
    [Abstract] [Full Text] [Related]

  • 4. A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.
    Petrucci MT, Giraldo P, Corradini P, Teixeira A, Dimopoulos MA, Blau IW, Drach J, Angermund R, Allietta N, Broer E, Mitchell V, Bladé J.
    Br J Haematol; 2013 Mar 26; 160(5):649-59. PubMed ID: 23293914
    [Abstract] [Full Text] [Related]

  • 5. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
    Ahn JS, Jung SH, Yang DH, Bae SY, Kim YK, Kim HJ, Lee JJ.
    Clin Lymphoma Myeloma Leuk; 2014 Oct 26; 14(5):389-94. PubMed ID: 24630919
    [Abstract] [Full Text] [Related]

  • 6. Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
    Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K.
    Cancer; 2005 Nov 15; 104(10):2141-8. PubMed ID: 16206291
    [Abstract] [Full Text] [Related]

  • 7. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
    Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.
    Ann Hematol; 2012 Feb 15; 91(2):249-56. PubMed ID: 21789621
    [Abstract] [Full Text] [Related]

  • 8. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients.
    Caballero-Velázquez T, López-Corral L, Encinas C, Castilla-Llorente C, Martino R, Rosiñol L, Sampol A, Caballero D, Serrano D, Heras I, San Miguel J, Pérez-Simón JA.
    Br J Haematol; 2013 Aug 15; 162(4):474-82. PubMed ID: 23772672
    [Abstract] [Full Text] [Related]

  • 9. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
    Bladé J, Cibeira MT, Rosiñol L.
    Acta Oncol; 2005 Aug 15; 44(5):440-8. PubMed ID: 16118077
    [Abstract] [Full Text] [Related]

  • 10. [Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].
    Hayashi T, Yasui H, Kawakami K, Ikeda H, Takahashi F, Kobayashi T, Nishimura S, Ishida T, Imai K, Shinomura Y.
    Rinsho Ketsueki; 2011 Mar 15; 52(3):136-41. PubMed ID: 21471701
    [Abstract] [Full Text] [Related]

  • 11. A pilot study of bortezomib in Korean patients with relapsed or refractory myeloma.
    Lee KW, Yun T, Song EK, Na II, Shin H, Bang SM, Lee JH, Lee ST, Kim JH, Yoon SS, Lee JS, Park S, Kim BK, Kim NK.
    J Korean Med Sci; 2005 Aug 15; 20(4):598-62. PubMed ID: 16100450
    [Abstract] [Full Text] [Related]

  • 12. Proteasome inhibitor bortezomib for the treatment of multiple myeloma.
    Cavo M.
    Leukemia; 2006 Aug 15; 20(8):1341-52. PubMed ID: 16810203
    [Abstract] [Full Text] [Related]

  • 13. [Effective combination therapy of bortezomib and dexamethasone for two patients with refractory multiple myeloma].
    Ikeda H, Hayashi T, Nojima M, Yasui H, Ikeda Y, Ishida T, Adachi M, Imai K.
    Rinsho Ketsueki; 2005 Apr 15; 46(4):269-73. PubMed ID: 16444959
    [Abstract] [Full Text] [Related]

  • 14. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
    Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC.
    Cancer; 2006 Mar 15; 106(6):1316-9. PubMed ID: 16470606
    [Abstract] [Full Text] [Related]

  • 15. Current status of bortezomib in the treatment of multiple myeloma.
    Cavo M.
    Curr Hematol Malig Rep; 2007 May 15; 2(2):128-37. PubMed ID: 20425361
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Proteasome inhibition in multiple myeloma.
    Kropff M, Bisping G, Wenning D, Berdel WE, Kienast J.
    Eur J Cancer; 2006 Jul 15; 42(11):1623-39. PubMed ID: 16820291
    [Abstract] [Full Text] [Related]

  • 18. Sequential treatment with bortezomib plus dexamethasone followed by autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Zheng D, Li J, Huang BH, Liu JR, Zou WY, Su C.
    Chin Med J (Engl); 2012 Dec 15; 125(24):4454-9. PubMed ID: 23253719
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.